ArticleInternational journal of clinical trials
Cannabidiol for treatment of irritability and aggressive behavior in children and adolescents with autism spectrum disorder: background and methods of the cannabidiol study in children with autism spectrum disorder study.
Article in International journal of clinical trials. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04520685 (CAnnabidiol Study in Children With Autism Spectrum DisordEr), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CAnnabidiol Study in Children With Autism Spectrum DisordEr (CASCADE): A Double-Blind, Placebo-Controlled Study to Investigate Efficacy and Safety of Cannabidiol in Children and Adolescents With Autism
Who cites it
3 citing papers in PubMed.
- Beyond neurons: Impact of cannabidiol on glial cells in ischemic stroke.Neural regeneration research · 2026Article
- Medical treatment of autism spectrum disorder in children: Current evidence, controversies, and clinical challenges.World journal of clinical pediatrics · 2026Article
- QEEG-Guided rTMS in Pediatric ASD with Contextual Evidence on Home-Based tDCS: Within-Cohort Reanalysis and Narrative Contextualization.Children (Basel, Switzerland) · 2025Article
Corrections and comments
- Update of
Authors and funding
12 authors.
Funding
Abstract
Background: Autism spectrum disorder (ASD) is a neurodevelopmental disorder commonly associated with behavioral challenges. There are few evidence based pharmacological interventions available for the treatment of behavioral symptoms associated with ASD. Cannabidiol (CBD), the non-intoxicating component of cannabis, has known neuroprotective, antiepileptic, anxiolytic, and antipsychotic effects and may be useful in treating the behavioral symptoms of ASD. Methods: We describe the research methods of a 27-week randomized placebo-controlled crossover trial to evaluate the safety and efficacy of oral CBD for the treatment of irritability and aggression associated with ASD, as measured by the irritability subscale of the aberrant behavior checklist-2 Conclusions: There is significant need for clinical research exploring alternative medications for the treatment of behavioral symptoms of ASD. Upcoming results from this trial will help answer the question of whether CBD may be a useful intervention in the management of ASD. Clinical trial registry: NCT04520685.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.